InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,620.85
(
0.42%
)
US TECH 100
19,324.00
(
0.59%
)
Dow Jones
40,890.49
(
0.14%
)
Brent Oil
75.69
(
-1.39%
)
Bitcoin
61,180.00
(
3.68%
)
Post# of 252939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120317
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Saturday, 03/26/2011 1:11:44 AM

Saturday, March 26, 2011 1:11:44 AM

Post# of 252939
Misconstruing the Ipilimumab data…

From the DNDN board on iV:

http://investorvillage.com/smbd.asp?mb=971&mn=395213&pt=msg&mid=10295896

3/25/2011 4:34:09 PM by bull trout

…compared to Provenge, the results from this study seem very weak.

About 85 percent of patients had little response to the drug ....The FDA said severe to fatal immune reactions occurred in 12.9 percent of patients during clinical trials. These numbers add up to 97.9% of the patients treated... that means the drug helped up to 2.1% of patients without nearly killing them.

No, that’s not at all what these data mean! Not one poster on that message board corrected this nonsensical statement but nine readers of the board recommended it, which may say something about what kinds of investors are long DNDN.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up